Arcutis, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Menlo Park CA United States (2016)

Organization Overview

First Clinical Trial
2017
NCT03392168
First Marketed Drug
2022
roflumilast (daliresp)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ARCUTIS | Arcutis Biotherapeutics, Inc. | ARCUTIS BIOTHERAPEUTICS INC | Arcutis, Inc.

Active Ingredients

Marketed Drugs (1)

roflumilast (daliresp) (2022)

Drugs in Phase 3 Trials (1)

roflumilast (daliresp) (20 trials)

Drugs in Phase 2 Trials (1)

arq-252 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Dermatitis, Seborrheic (Phase 2)

Eczema (Phase 2)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 2